ArticleTranslational oncology2026
11-Oxo-mogroside V attenuates lung adenocarcinoma progression by disrupting metabolic homeostasis and suppressing TGFβ2/Myc-dependent oncogenic signaling.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality worldwide, with nonsmokers comprising a notable proportion of cases. The complexity of its molecular pathogenesis poses substantial challenges for the development of effective therapeutic strategies. Traditional Chinese medicine-derived compounds have garnered attention for their multi-target engagement and favorable safety profiles.
objectiveThis study aimed to characterize the antitumor effects and elucidate the mechanistic basis of 11-oxo-mogroside V, a bioactive triterpenoid saponin from Siraitia grosvenorii, in LUAD.
methodsIn vitro assays (CCK-8, flow cytometry, wound-healing, metabolic measurements) were performed on lung adenocarcinoma cells. In vivo efficacy was evaluated using a xenograft mouse model with bioluminescent monitoring and TUNEL staining. Transcriptomic profiling, molecular docking, immunoblotting, and co-immunoprecipitation elucidated mechanistic pathways.
results11-oxo-mogroside V (800 μg/mL, 72 h) significantly reduced cell viability, induced G0/G1 arrest, and promoted apoptosis (apoptotic rate increased from 3.01% to 12.00%, P < 0.0001). Migration was suppressed (wound closure reduced from 77.66% to 43.98%, P < 0.0001). Metabolic disruption was evidenced by decreased intracellular ATP, glucose uptake, and LDH activity. In vivo, 11-oxo-mogroside V (100 mg/kg, daily) markedly inhibited tumor growth (photon flux reduced from 2.65 × 10¹⁰ to 1.50 × 10¹⁰, P < 0.0001) and increased apoptosis (TUNEL-positive cells from 0.40% to 5.97%, P < 0.0001). Mechanistically, RNA-seq analysis and molecular docking suggested TGFB2, HDAC1, and c-Myc as potential molecular targets, with docking simulations indicating favorable binding affinities. Western blot confirmed downregulation of TGFB2, Smad2/3, TGIF, HDAC1, c-Myc, and Bcl2, alongside upregulation of Bax, with co-IP demonstrating HDAC1-TGIF1 interaction.
conclusion11-oxo-mogroside V exerts potent anti-LUAD activity by disrupting metabolic homeostasis and suppressing TGFβ2/HDAC1/c-Myc signaling, positioning it as a promising lead compound for therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.